Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:21:02 EDT Mon 13 May 2024
Enter Symbol
or Name
USA
CA



News for U:FATE from 2023-05-14 to 2024-05-13 - 21 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-09 16:01U:FATENews ReleaseFate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
2024-05-09 08:30U:FATENews ReleaseFate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
2024-05-06 08:00U:FATENews ReleaseFate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
2024-05-03 16:30U:FATENews ReleaseFate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
2024-04-22 16:30U:FATENews ReleaseFate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
2024-04-03 08:00U:FATENews ReleaseFate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
2024-04-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2024-03-19 08:45U:FATENews ReleaseFate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
2024-03-05 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2024-03-01 08:00U:FATENews ReleaseFate Therapeutics to Present at Upcoming March Investor Conferences
2024-02-26 16:01U:FATENews ReleaseFate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
2024-02-15 08:00U:FATENews ReleaseFate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
2024-02-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-01-08 08:00U:FATENews ReleaseFate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
2023-12-13 17:00U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-08 16:01U:FATENews ReleaseFate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
2023-10-25 08:00U:FATENews ReleaseFate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
2023-08-31 08:00U:FATENews ReleaseFate Therapeutics to Present at Upcoming September Investor Conferences
2023-08-08 16:01U:FATENews ReleaseFate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
2023-07-28 08:00U:FATENews ReleaseFate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
2023-05-31 08:00U:FATENews ReleaseFate Therapeutics to Present at Upcoming June Investor Conferences